Abnova Taiwan (4133.TW) Stock Price

Abnova Taiwan Price

TWSE·CLOSED
19.10
​
Market closed

Revenue has compounded at 5.5% per year over the past 19 years to 351.30 M TWD. Earnings per share have grown at 17.5% per year over the last 18 years. Abnova Taiwan's net margin stands at -0.3%, down from 6.3% several years earlier. Abnova Taiwan currently offers a dividend yield of about 4.71%.

Abnova Taiwan stock price

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Abnova Taiwan business model & stock analysis

Abnova Taiwan Corp is a global biotechnology company specializing in the production of antibodies used in the diagnosis and treatment of various diseases. Founded in 2002 in Taipei, the company has been at the forefront of utilizing new technologies to automate and streamline the antibody production process. This has allowed Abnova Taiwan Corp to become one of the largest antibody manufacturers worldwide. The company's business model focuses on increasing the efficiency of biotech productions and improving the quality of biochemical reagents. In addition to antibody production, the company also develops and produces recombinant proteins and targeted therapeutics. Abnova Taiwan Corp offers a wide range of in-vitro diagnostic products and is actively involved in cancer research. The company distributes its antibodies and proteins globally through partnerships with distributors and agents. Overall, Abnova Taiwan Corp is a leading biotech company that continually strives to maintain excellence in product quality and efficiency through technological innovation.

Frequently asked questions about Abnova Taiwan

The business model of Abnova Taiwan Corp is focused on bio-technology and life sciences. Abnova specializes in the production and distribution of high-quality antibodies and related reagents for academic and industrial researchers worldwide. By leveraging their extensive expertise in protein science and advanced technologies, Abnova aims to contribute to advancements in medical research and drug discovery. Abnova's products and services encompass a wide range of research areas including genomics, proteomics, cell biology, and diagnostics. Through their innovative solutions and commitment to quality, Abnova Taiwan Corp strives to support the scientific community in their pursuit of breakthrough discoveries and improved healthcare.

Abnova Taiwan Corp is primarily active in the biotechnology industry.

The main competitors of Abnova Taiwan Corp in the market include companies like Thermo Fisher Scientific, Merck KGaA, Agilent Technologies, and Bio-Rad Laboratories.

Abnova Taiwan Corp is a renowned biotechnology company based in Taiwan. Established in 2002, it specializes in the development and commercialization of innovative tools and solutions for life science research. Abnova Taiwan Corp has a rich history of delivering high-quality products and services to researchers worldwide, empowering them to achieve breakthroughs in various fields including cancer research, drug discovery, and personalized medicine. With an extensive portfolio of antibodies, proteins, and assays, the company has gained recognition for its commitment to advancing scientific knowledge and improving human health. Abnova Taiwan Corp continues to be a leading player in the global biotechnology industry, dedicated to driving advancements and contributing to scientific discovery.

Abnova Taiwan Corp has achieved significant milestones since its inception. The company has successfully developed over 20,000 high-quality antibodies and more than 3,000 recombinant proteins, establishing itself as a leader in the life sciences research industry. Abnova Taiwan Corp has also made considerable progress in the production of innovative diagnostic kits and pharmaceutical-related products. With its dedication to research and development, the company has gained recognition for its contributions to advancing biomedical research. Additionally, Abnova Taiwan Corp's collaborations with renowned academic institutions and pharmaceutical companies have further strengthened its position in the market.

Abnova Taiwan Corp is primarily present in Taiwan.

Abnova Taiwan Corp represents values such as innovation, collaboration, and integrity in its corporate philosophy. It focuses on developing and providing high-quality antibodies and other research tools to accelerate scientific discoveries. With a commitment to excellence and customer satisfaction, Abnova Taiwan Corp aims to support researchers worldwide in their pursuit of understanding human health and diseases. By continuously advancing scientific knowledge and delivering cutting-edge technologies, the company demonstrates its dedication to improving global healthcare and making a positive impact on society.

9 analysts currently rate the Abnova Taiwan stock: 0 recommend buying, 3 holding and 6 selling.

Converted at the current exchange rate, the Abnova Taiwan share trades at 0.53 EUR (19.10 TWD).

The Abnova Taiwan share (4133.TW) is listed on 1 stock exchanges, including: TWSE (Taiwan) (4133.TW).

Abnova Taiwan Corp is an innovative company in the field of biotechnology, specializing in the development of products for medical research and diagnostics. The company is headquartered in Taiwan and operates worldwide. The business model of Abnova is based on three pillars: product development and distribution, diagnostics, and laboratory services. The company offers a wide range of products and services for medical research and diagnostics, working closely with customers and partners to meet their needs and requirements. Product development and distribution Abnova develops and produces antibodies, proteins, peptides, and other biological molecules for research and diagnostics in a variety of applications. The company works closely with its customers to meet specific needs and requirements in terms of quality, quantity, and functionality. Abnova also offers innovative products for personalized medicine, tailored to the individual needs of the patient. These products are based on the patient's genetic information, enabling precise diagnostics and treatment. Diagnostics Abnova offers numerous diagnostic products for medical research and diagnostics, including antibodies, proteins, peptides, kits, and assays. These products are used for biomarker identification, disease diagnosis and treatment, and personalized medicine. Laboratory services Abnova also offers extensive laboratory services for medical research and diagnostics, including protein production, peptide production, antibody production, assay development and validation, and diagnosis and treatment support. The company also has extensive experience in genetic analysis and offers corresponding services. Abnova always goes the extra mile to provide its customers with high-quality products and services. The company continuously invests in research and innovation to improve its products and processes and meet the challenges of medical research and diagnostics. In summary, Abnova Taiwan Corp is an innovative company in the field of biotechnology, offering a wide range of products and services for medical research and diagnostics to its customers. The business model of Abnova is based on the pillars of product development and distribution, diagnostics, and laboratory services, with the company continuously investing in research and innovation to provide its customers with high-quality products and services.

The revenue cannot currently be calculated for Abnova Taiwan.

The profit cannot currently be calculated for Abnova Taiwan.

The P/E ratio cannot be calculated for Abnova Taiwan at the moment.

The P/S cannot be calculated for Abnova Taiwan currently.

The Eulerpool Quality Score for Abnova Taiwan is 2/10.

The ISIN of Abnova Taiwan is TW0004133004. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of Abnova Taiwan is 4133.TW. The ticker symbol is used to trade Abnova Taiwan shares on the stock exchange.

Fair ValueTerminal
19.48 TWD
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Life Sciences Tools & Services
Number of shares
Employees
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Website abnova.com
Country
Taiwan
Currency
TWD
Initial public offering
May 27, 2008
ISIN
TW0004133004
Cusip
Y0005B111
Sedol
B39GDD3
Market capitalization
1.16 B TWDSmall Cap
52-Week Range
PEG
—
P/E ratio
P/Ee
—
P/S
P/Se
—
EV/EBIT
46.75
P/B Ratio
0.92
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
-0.09 %
Dividend
Dividend yield
4.71 %
Payout Ratio
-4,776.39 %
Dividend growth Ø5Y
8.45 %
Dividend payments per year
1
Dividend paid since
16 years
Dividend not reduced since
1 year
Dividend increased since
1 year
Dividend withholding tax
21.00 %
Last updated Nov 20, 2026, 3:36 AM

Abnova Taiwan Peer Group

Abnova Taiwan Ticker

TWSE · 4133.TW

Abnova Taiwan FIGI

4133:TT (Taiwan Stock Exchange) · BBG000G56MF9

All fundamentals and in-depth analysis of Abnova Taiwan

Our stock analysis for Abnova Taiwan stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Abnova Taiwan. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.